- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | B.Riley initiates coverage on OKYO Pharma stock with Buy rating | 1 | Investing.com | ||
| Mo | B.Riley startet Coverage für OKYO Pharma mit Kaufempfehlung und hohem Kursziel | 1 | Investing.com Deutsch | ||
| Mi | OKYO Pharma: Dem Chairman nahestehendes Unternehmen kauft Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | OKYO Pharma Announces Chairman and Founder Acquires Shares | 198 | GlobeNewswire (Europe) | LONDON and NEW YORK, Dec. 03, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| Mi | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.11. | Okyo Pharma chairman increases stake with new share acquisition | 1 | Investing.com | ||
| 21.11. | Okyo Pharma: Chairman stockt Beteiligung nach Kursrückgang auf | 2 | Investing.com Deutsch | ||
| 21.11. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 291 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 21, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 18.11. | OKYO Pharma to Present at OIS XV in San Diego | 174 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 18, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 18.11. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.10. | OKYO Pharma to Present at BIO-Europe 2025 in Vienna | 269 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 29, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
| 29.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.10. | Insider-Kauf bei OKYO Pharma: Gesellschaft des Executive Chairman erwirbt 210.000 Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| 16.10. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 233 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 16, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 16.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 216 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 604,20 | -0,53 % | IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge? | ||
| BIOXCEL THERAPEUTICS | 1,850 | -2,63 % | BioXcel Therapeutics: Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions | ||
| ADAPTIMMUNE THERAPEUTICS | 0,033 | +6,45 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,714 | -0,32 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,641 | -2,26 % | ANAVEX LIFE SCIENCES CORP zündet Kursexplosion! | ||
| CELLAVISION | 13,580 | -3,28 % | CellaVision: CellaVision receives CE marking according to IVDR Class C for CellaVision Bone Marrow Aspirate Application | Today, CellaVision has reached another important milestone and announces that its new CellaVision Bone Marrow Aspirate (BMA) Application has received CE marking approval as a Class C product under the... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 4,160 | +1,46 % | Precision BioSciences launches $75M stock and warrant offering | ||
| ZYMEWORKS | 23,000 | +0,88 % | Zymeworks stock initiated with Market Outperform rating by Citizens | ||
| VTV THERAPEUTICS | 25,000 | -4,58 % | vTv Therapeutics Inc.: vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 9,880 | 0,00 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,450 | -1,77 % | ISS recommends shareholders vote for Neuphoria's board nominees | ||
| NUVATION BIO | 8,440 | -1,63 % | Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result | ||
| MIRA PHARMACEUTICALS | 1,170 | -0,85 % | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| PLIANT THERAPEUTICS | 1,150 | +4,55 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment... ► Artikel lesen | |
| ONCONETIX | 2,900 | +1,75 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,920 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.